A federal appeals court decision reviving hundreds of lawsuits over Tylenol use in pregnancy has put Kenvue (KVUE) under closer scrutiny, highlighting fresh legal risk and raising new questions for investors tracking the stock.

Kenvue’s 1 day share price return of 1.28% and 7 day share price return of 1.69% sit against a 30 day share price return of 6.01% and 90 day share price return of 10.64%. The year to date share price return of 11.03% contrasts with a 1 year total shareholder return that declined 7.78% and a 3 year total shareholder return that declined 12.72%, suggesting recent momentum has picked up even as longer term holders have experienced weaker results.

If this legal setback has you reassessing healthcare exposure, it may also be a good moment to look across the sector and see what stands out in 40 healthcare AI stocks

After Kenvue’s recent rebound, along with a legal overhang that is now back in focus, it is fair to ask whether most of the easy upside has already played out or if the current valuation still points to room ahead.

Most Popular Narrative: 1% Undervalued

The most followed Kenvue narrative pins fair value close to the recent $19.23 close, implying only a small valuation gap but with precise assumptions behind it.

Strategic focus on streamlining operations, including reducing internal complexity and concentrating resources on best-selling brands and key regions, is expected to unlock cost efficiencies, improve decision-making speed, and enhance net margins and earnings over time.

Curious what justifies pricing Kenvue only slightly below a modeled fair value? The narrative leans on measured revenue growth, firmer margins, and a premium earnings multiple. The exact mix of those three drivers is where the story gets interesting.

Result: Fair Value of $19.50 (UNDERVALUED)

However, Kenvue’s valuation story still faces pressure from legal uncertainty around Tylenol and the risk that e-commerce execution or portfolio simplification does not meet current expectations.

Another View: How Kenvue Looks On Earnings Multiples

While the narrative around Kenvue leans on a modeled fair value of $19.50, the current P/E of 22.8x tells a more mixed story. It sits higher than the global Personal Products industry at 18.8x, slightly above a fair ratio of 21.3x, yet well below a 51.4x peer average. This leaves you to judge whether this points to risk or room.

To see how those earnings multiples stack up against detailed valuation work, including the fair ratio that the market could move toward over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on Kenvue split between legal risk and earnings support, you may want to act promptly and review the data yourself to weigh both sides through the 3 key rewards and 2 important warning signs

Looking for more ideas beyond Kenvue?

Do not stop your research with Kenvue alone. Widen your opportunity set now using focused stock lists that can surface ideas you might otherwise miss.

• Target income first and stress less about yield hunting by scanning resilient payers through the 8 dividend fortresses.
• Hunt for quality priced below what the fundamentals suggest by reviewing the 46 high quality undervalued stocks.
• Prioritize strength and sleep better at night by filtering for companies in the 80 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.